We front the investment and carry the development risk, then partner for value.
Known molecules chosen on need, feasibility and barriers.
In our Bangalore laboratory and through our CMO and CRO network.
A de-risked product with a complete development package.
The partner licenses the de-risked asset at the gate and leads the path to market.
Joint workstreams and shared decisions, combining our formulation science with the partner's capabilities.
The partner shares the investment and the development risk, with the program jointly governed.
Technology transfer follows each route, with commercial supply through our CMO network or the partner's site.
Products are chosen on unmet need, market attractiveness, regulatory feasibility, competitive barriers, and licensing potential — not novelty for its own sake.
Development takes place at our own state-of-the-art R&D laboratory in Bangalore, India — staffed by 50+ scientists, and supplemented by academic partnerships providing on-demand access to advanced platforms including SEM, XRD, LC-MS, NGS, and high-throughput screening.
We work with pharmaceutical companies, investors, CROs, CDMOs, and strategic partners across our UK and India operations and global markets.
Development-ready products are licensed, co-developed, or transferred for commercialisation — converting technical assets into commercial value.
Our model concentrates investment where value is created and keeps fixed assets out of the equation.
We develop through a network of qualified CMOs and CROs, so investment funds formulation, analytical and regulatory work rather than plant and equipment.
Work starts on existing partner capacity instead of waiting for facilities to be built, commissioned and validated.
Processes are developed with technology transfer in mind, so a licensee can manufacture at the site or through the partner it prefers.
We self-fund programs through to a de-risked, licensable state, concentrating our investment on the technical and regulatory risks partners most want removed.